Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma The European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study
Main Authors: | Penel, N, Glabbeke, M V, Mathoulin-Pelissier, S, Judson, I, Sleijfer, S, Bui, B, Schoffski, P, Ouali, M, Marreaud, S, Brouste, V, Duhamel, A, Hohenberger, P, Blay, J-Y |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2011
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101912/ |
Similar Items
-
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
by: Sleijfer, S, et al.
Published: (2012) -
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
by: Nielsen, O. S., et al.
Published: (1998) -
Pazopanib for the treatment of soft-tissue sarcoma
by: Heudel, Pierre, et al.
Published: (2012) -
Retroperitoneal soft tissue sarcoma
by: Zepeda, Ernesto, et al.
Published: (2007) -
Soft tissue sarcomas of the kidney
by: Olivia Köhle, et al.
Published: (2015-03-01)